Proton Pump Inhibitors Intake and Iron and Vitamin B12 Status: a Prospective Comparative Study with a Follow up of 12 Months
Total Page:16
File Type:pdf, Size:1020Kb
Open Access Maced J Med Sci electronic publication ahead of print, published on March 12, 2018 as https://doi.org/10.3889/oamjms.2018.142 ID Design Press, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. https://doi.org/10.3889/oamjms.2018.142 eISSN: 1857-9655 Basic Science Proton Pump Inhibitors Intake and Iron and Vitamin B12 Status: A Prospective Comparative Study with a Follow up of 12 Months Hasime Qorraj-Bytyqi1, Rexhep Hoxha1, Shemsedin Sadiku2, Ismet H Bajraktari3, Mentor Sopjani4, Kujtim Thaçi5, Shpetim Thaçi4, Elton Bahtiri1,6* 1Department of Pharmacology, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo; 2Clinic of Hematology, University Clinical Center of Kosovo, Prishtina, Kosovo; 3Clinic of Rheumatology, University Clinical Center of Kosovo, Prishtina, Kosovo; 4Department of Preclinical Studies, Faculty of Medicine, University of Prishtina, Kosovo; 5Institute of Biochemistry, University Clinical Center of Kosovo, Prishtina, Kosovo; 6Clinic of Endocrinology, University Clinical Center of Kosovo, Prishtina, Kosovo Abstract Citation: Qorraj-Bytyqi H, Hoxha R, Sadiku S, Bajraktari BACKGROUND: Proton pump inhibitors (PPIs) represent the most widely prescribed antisecretory agents, but IH, Sopjani M, Thaçi K, Thaçi S, Bahtiri E. Proton Pump their prolonged use, may influence iron and vitamin B12 status, which could have important implications for Inhibitors Intake and Iron and Vitamin B12 Status: A Prospective Comparative Study with a Follow up of 12 clinical practice. Months. Open Access Maced J Med Sci. https://doi.org/10.3889/oamjms.2018.142 AIM: We undertook this study aiming to investigate the association between PPIs use for 12 months and potential Keywords: PPIs; Iron: Ferritin; Vitamin B12; changes in iron and vitamin B12 status, as well as whether this potential association varies among four specific Homocysteine PPI drugs used in the study. *Correspondence: Elton Bahtiri. Department of Pharmacology, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo. E-mail: elton.bahtiri@uni- METHODS: A total of 250 adult subjects were recruited into this study, of which 200 subjects were PPIs users pr.edu while 50 subjects belonged to the control group. Serum iron, ferritin, vitamin B12, and homocysteine (Hcy) levels Received: 05-Oct-2017; Revised: 20-Feb-2018; were measured before the start of the study and after 12 months. Mann - Whitney U test and Kruskal - Wallis test Accepted: 28-Feb-2018; Online first: 12-Mar-2018 was used to compare the baseline characteristics of the study groups, while Wilcoxon test was used to analyse Copyright: © 2018 Hasime Qorraj-Bytyqi, Rexhep post - pre differences. Hoxha, Shemsedin Sadiku, Ismet H Bajraktari, Mentor Sopjani, Kujtim Thaçi, Shpetim Thaçi, Elton Bahtiri. This is RESULTS: Statistical analysis showed significant changes within PPIs group and specific PPIs subgroups an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 between the two-time points in serum ferritin and vitamin B12 levels, respectively, while no significant changes in International License (CC BY-NC 4.0) serum iron and homocysteine levels were shown. However, subsequent diagnosis of hypoferremia and Funding: This research was partly sponsored by a grant hypovitaminosis B12 in the whole study sample at 12 months was established in only 3.8% and 2.9% of the from the Ministry of Education, Science and Technology of Kosovo subjects, respectively. Competing Interests: The authors have declared that no competing interests exist CONCLUSION: PPIs use for 12 months did not result in clinically significant iron and/or vitamin B12 deficiency; thus, these findings argue routine screening under normal circumstances, although monitoring in elderly and malnourished may be of precious value. Introduction potent suppression of gastric acid secretion by parietal cells, which could have important implications for clinical practice [5] [6]. Relatively few studies have Proton pump inhibitors (PPIs) represent the specifically investigated the association between PPIs most widely prescribed antisecretory agents [1] use and iron status and/or risk of anemia while what is Prolonged PPIs use is not without consequences, known about the association between PPIs use and however [1] [2]. Concerns have been raised about a vitamin B12 deficiency is largely based on case - possible association between prolonged PPIs use and reports or retrospective observational studies with increased risk for vitamin and mineral deficiencies [3] considerable inconsistency in the findings [7] [8] [9] [4]. It has been suggested that their prolonged use [10] [11] [12] [13] [14] [15] [16]. Moreover, they have may influence iron and vitamin B12 status due to failed to provide appropriate monitoring _______________________________________________________________________________________________________________________________ Open Access Maced J Med Sci. 1 Basic Science _______________________________________________________________________________________________________________________________ recommendations in this regard [17]. Most of the participants were screened for exclusion mentioned previous studies provided only the data comparing above criteria. “treatment” with “no treatment”, we therefore A total of 250 adult subjects were recruited undertook this study aiming to prospectively into this study, of which 200 subjects were PPIs users investigate the association between PPIs use for 12 of orally taken dosage forms of PPIs while 50 subjects months in new - users and potential changes in iron belonged to the control group (PPIs nonusers). PPIs and vitamin B12 status, as well as whether this users were divided into four matched groups, each of potential association varies among four specific PPI them consisting of 50 subjects: patients on drugs used in the study. Also, the incidence of new- omeprazole therapy (20 mg/day), patients on onset hypoferremia and hypovitaminosis B12 and esomeprazole therapy (20 mg/day), patients on hyperhomocysteinemia (HHcy) during the study was lansoprazole therapy (30 mg/day), and patients on assessed. pantoprazole therapy (40 mg/day). Material and Methods The methodology of this open - labelled prospective study is described in greater detail elsewhere [18] [19]. Briefly, the study population consisted of subjects aged 18 to 65 years with a confirmed diagnosis of osteoarthritis of small joints of the hands and on chronic NSAIDs that indicated to initiate gastroprotective maintenance therapy with Figure 1: Study design [18] PPIs. Control group consisted of 50 matched healthy participants and with no gastrointestinal or other risk factors present for iron and vitamin B12 deficiency. All study participants provided written The participants belonging to the groups under informed consent. Before the initiation of the study treatment with PPIs were contacted every 3 months was obtained the approval of the study protocol from by telephone to assess the adherence to PPIs and the the local ethical committees of the University Clinical potential adverse effects, while participants in the Center of Kosova and Faculty of Medicine, University control group were contacted by telephone after 12 of Prishtina. months. Fasting blood samples were collected from Subjects were enrolled in the study only if the antecubital vein at 8 AM, and were centrifuged they had serum iron, ferritin and vitamin B12 levels within the first hour to separate the serum. The greater than lower reference limit provided by the lab measurements of serum iron, ferritin, vitamin B12 and (Table 1). Subjects were not included in the study if homocysteine levels were done before the start of the they were using parenteral and/or oral supplements of study (at baseline) and after 12 months. Serum iron, iron, vitamin B12 and folic acid, respectively, as well ferritin and homocysteine (enzymatic test) as any of the antisecretory agents (including PPIs) concentrations were measured simultaneously using during preceding 12 months. Also, subjects with automated analyser, COBAS Integra 400 Plus (Roche known hypersensitivity to any drug were excluded. Diagnostics, Switzerland), while serum vitamin B12 Subjects were also excluded from the study if they concentrations were measured by were blood donors, were on vegetarian diet, were Electrochemiluminescence Immunoassay using chronic alcohol abusers, were using concomitantly Elecsys 2010 system (Roche Diagnostics, drugs (namely metformin, thyroid hormone Switzerland). Hypoferremia was defined as serum supplements, antiepileptic drugs, anticoagulant drugs, levels of <10.6 μmol/l in male and < 6.6 μmol/l in oral contraceptives, glucocorticoids) and/or had female, hypoferritinemia was defined as serum levels diseases that may affect iron and vitamin B12 status of < 30 ng/ml in male and < 13 ng/ml in female, (namely dementia, acute inflammatory diseases, hypovitaminosis B12 was defined as serum levels of malabsorption diseases, abnormal uterine, < 191 pg/ml, and hyperhomocysteinemia was defined gastrointestinal or urinary bleeding, patients with as serum levels of >15 μmol/l. atrophic gastritis or gastrectomy, thyroid diseases, renal diseases, cardiovascular diseases, neoplastic All the study results are expressed as the diseases including leukemias and lymphomas). mean ± standard deviation and as percentages, as Subjects were not included if they were pregnant, appropriate. The baseline continuous characteristics lactating